What Relay managed with a combo Scorpion might be able to do with STX-478 monotherapy.
ApexOnco Front Page
Recent articles
Despite seeing dose-limiting toxicities, the group is going higher with its KRAS G12D project.
Patients' expression of CEACAM5 might hold the key to activity after all.
Spectrum’s poziotinib failed in HER2 exon 20 lung cancer, but that isn’t stopping Boehringer and Bayer.
The group is going beyond EGFR exon 20 insertions, but still has work to do to justify its valuation.
The fortunes of RLY-2608 reverse, and a pivotal study will follow.
Akeso’s data look impressive, but perhaps not impressive enough to sustain Summit’s valuation.
The mid-stage Ideate-Lung01 study bears out ifinatamab-dxd’s efficacy in small-cell lung cancer.
